US 12,076,323 B2
Treatment of hair loss disorders with deuterated JAK inhibitors
Amanda T. Wagner, Watertown, MA (US); James V. Cassella, Essex, CT (US); Philip B. Graham, Boston, MA (US); Virginia Braman, Winchester, MA (US); Vinita Uttamsingh, Chestnut Hill, MA (US); Jana Von Hehn, Newton, MA (US); and Colleen E. Hamilton, Carlisle, MA (US)
Assigned to Sun Pharmaceuticals Industries, Inc., Princeton, NJ (US)
Filed by Sun Pharmaceutical Industries, Inc., Princeton, NJ (US)
Filed on Dec. 5, 2019, as Appl. No. 16/704,402.
Application 16/704,402 is a continuation of application No. 16/098,338, granted, now 10,561,659, previously published as PCT/US2017/031142, filed on May 4, 2017.
Claims priority of provisional application 62/492,758, filed on May 1, 2017.
Claims priority of provisional application 62/466,358, filed on Mar. 2, 2017.
Claims priority of provisional application 62/434,404, filed on Dec. 14, 2016.
Claims priority of provisional application 62/419,237, filed on Nov. 8, 2016.
Claims priority of provisional application 62/418,774, filed on Nov. 7, 2016.
Claims priority of provisional application 62/338,869, filed on May 19, 2016.
Claims priority of provisional application 62/331,827, filed on May 4, 2016.
Prior Publication US 2020/0222408 A1, Jul. 16, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 9/00 (2006.01); A61K 9/20 (2006.01); A61P 17/14 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 9/0053 (2013.01); A61K 9/2009 (2013.01); A61K 9/2013 (2013.01); A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61P 17/14 (2018.01)] 29 Claims
 
1. A method of treating a hair loss disorder in a human subject, the method comprising administering to the human subject 16 mg/day of a compound represented by the following structural formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein each position in Compound (I) designated specifically as deuterium has at least 95% incorporation of deuterium.